Effect of iron therapy in patients with heart failure in mild to moderate anemia.

efficacy of intravenous iron therapy vs oral iron therapy on haemoglobin, exercise tolerance, cardiovascular risk and quality of life in patients having heart failure in mild to moderate iron deficiency anaemia - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/093719

Enrollment

100

Registered

2025-08-26

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I50- Heart failure Health Condition 2: E611- Iron deficiency

Interventions

Intervention1: Intravenous iron therapy (Inj. ferric carboxymaltose): Drug to be administered intravenously, with the dosage calculated using Ganzonis Formula. The duration of administration will be d

Eligibility

Inclusion criteria

Inclusion criteria: Patients with heart failure fulfilling the Framinghams criteria. Patients with mild to moderate IDA i.e. Hb levels between 8-10 gm%.

Exclusion criteria

Exclusion criteria: Patients with acute or decompensated heart failure ,severe iron deficiency anemia , aplastic anemia, anemia of chronic disease , sideroblastic anemia. Patients with creatinine more than 2

Design outcomes

Primary

Measure	Time frame
To study efficacy of intravenous iron therapy vs oral iron therapy in patients having heart failure with mild to moderate ironTimepoint: At baseline , 3 months and 9 months	—

Secondary

Measure	Time frame
To study effect of intravenous iron vs oral iron on hemoglobin, exercise tolerance and quality of life in patients with heart failure with mild to moderate anemia.Timepoint: At baseline , 3 months and 9 months	—

Countries

India

Contacts

Public ContactDr.Shikha Mundra

Datta Meghe Institute of Higher Education and Research

drshilpagaidhane@gmail.com9673288822

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026